MétaCan
Menu
← Back to cohort
Record W7117418243 · doi:10.1002/alz70855_102371

Evaluating the Efficacy and Risks of Early Lecanemab Treatment in APOE4 Humanized Alzheimer's Disease Mouse Models

2025· article· en· W7117418243 on OpenAlexaff
Arash Salahinejad, Amr Eed, Mohammad H Alipour, Kellly Summers, Kate M. Onuska, Luke Smolders, Ebrima Gibbs, Czarina Evangelista, Lisa M Saksida, Timothy J Bussey, Neil R. Cashman, Johanne Kaplan, Scott Napper, Taylor W. Schmitz, Vânia F. Prado, Ravi S. Menon, Marco AM Prado

Bibliographic record

VenueAlzheimer s & Dementia · 2025
Typearticle
Languageen
FieldMedicine
TopicAlzheimer's disease research and treatments
Canadian institutionsLawson Health Research InstituteRobarts Clinical TrialsUniversity of SaskatchewanAmorfix (Canada)University of British ColumbiaWestern University
Fundersnot available
KeywordsDiseaseHumanized mouseMonoclonal antibodyAntibody therapyCognitionGenetic testingClinical trial

Abstract

fetched live from OpenAlex

Abstract Background Alzheimer's disease (AD) is the leading cause of dementia. AD disproportionately affects APOE4 carriers, who experience accelerated amyloid β (Aβ) accumulation, including cerebral amyloid angiopathy (CAA). While monoclonal antibodies (mAbs) like lecanemab reduce amyloid plaques, their use is complicated by amyloid‐related imaging abnormalities (ARIA‐likely related to brain bleeds), particularly in APOE4 carriers. Lecanemab, a humanized mAb targeting Aβ protofibrils, but still poses an enhanced risk for APOE4 carriers. This study explores whether early lecanemab treatment can reduce the risk of microbleeds and prevent cognitive deficits as well as brain atrophy in APOE4 humanized AD mouse models. Methods Advanced AD mouse models with humanized APP (hApp), Tau (hMAPT), and APOE3/APOE4 genes were used. The murine version of lecanemab (mAb158) was synthesized and shown to target synthetic Aβ oligomers and pre‐fibrillar amyloid in these models. Starting at 3 months of age, hApp NL‐F ‐hMAPT‐APOE4 and hApp NL‐F ‐hMAPT‐APOE3 mice received mAb158 (20 mg/kg weekly for 26 weeks) or vehicle (PBS). Cognitive performance was assessed at 6, 9, and 12 months using a touchscreen‐based Continuous Performance Test (CPT) to assess attention. At study end, brain tissues were analyzed via light‐sheet microscopy, immunohistochemistry, Prussian Blue staining, and ELISA to evaluate plaques, amyloid deposits, microbleeds, and Aβ levels. Results Immunohistochemistry and light‐sheet microscopy revealed significant amyloid accumulation in the brain and blood vessels of hApp NL‐F ‐hMAPT‐APOE4 mice, from 6 months of age onward, compared to hApp NL‐F ‐hMAPT‐APOE3. In the mAb158 treated mice, insoluble Aβ accumulation was negligible in both genotypes at 9 months of age and significantly reduced at 15 months of age in hApp NL‐F ‐hMAPT‐APOE4 mice compared to vehicle. hApp NL‐F ‐hMAPT‐APOE4 mice showed CPT deficits starting at 6 months under vehicle and mAb158, with no difference in performance between treatment groups. Preliminary analyses suggest mAb158 causes microhemorrhages. Conclusions Early mAb158 treatment reduces key Alzheimer's disease pathology but fails to prevent attention deficits in hApp NL‐F ‐hMAPT‐APOE4 mice and may increase microbleeds in this vulnerable group. By combining new generation mouse models of genetic AD risk with translational cognitive and imaging biomarkers, we propose a preclinical platform to better predict the safety and efficacy of monoclonal antibody treatments.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.155
GPT teacher head0.421
Teacher spread0.266 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & Dementia→Same topicAlzheimer's disease research and treatments→French-language works237,207→